High-Dose Omega-3 EPA shows promise for preventing Migraine - Clinical trial
High-dose eicosapentaenoic acid (EPA) monotherapy for 12 weeks showed superior efficacy, safety, and tolerability in patients with episodic migraine (EM), emphasizing its potential as a promising prophylactic option for managing this condition
FAB RESEARCH COMMENT:
In a new clinical trial, supplementation with high-EPA fish oils for 12 weeks led to significant benefits for the prevention of episodic migraine.- Frequency and severity of migraines and associated disability were significantly reduced in patients receiving the fish oil vs placebo treatment.
- Supplementation also significantly reduced psychological distress (anxiety and depression symptoms) and improved overall quality of life.
Previous clinical trials of 'omega-3 for migraine' have already reported benefits, but overall findings have been regarded as 'inconclusive' - as most trials have been small, and with different formulations and dosages used. The current study used a dose of 2g/day of fish oils, providing 1.8g EPA /day.
For full details of this research (which is open access), please see:
Highlights provided there include:
- The need for enhanced and better-tolerated approaches for effective migraine prevention remains strong.
- Neuroinflammatory pathways with nutraceutical intervention may be promising targets for migraine.
- High-dose EPA could be a promising prophylactic option for managing episodic migraine.
- Patients receiving high-dose EPA showed significant improvements in psychological symptoms associated with episodic migraine.
- The EPA treatment demonstrated a lack of major adverse events, underscoring its safety for use in patients with episodic migraine.
Two recent publications also reported that omega-3 supplements may be a 'highly promising' intervention for prevention and clinical management of migraine - which these new findings clearly support.
1) A review of evidence for the many different mechanisms by which fish oils might help reduce migraine.
These include the ability of omega-3 EPA/DHA to reduce both inflammation and pain sensitivity (via many independent mechanisms), as well as their benefits for mitochondrial health and emotional regulation.
The authors also noted the established safety of these omega-3 in clinical trials across numerous different conditions.
2) a meta-analysis showing high-dose omega-3 outperforms medications for migraine
A network analysis of 40 clinical trials (involving over 6600 patients) found that high-dose omega-3 supplementation was both more effective, and more acceptable to patients, than the best current pharmaceutical treatments for migraine prevention. See:
Finally - rather than using supplements:
3) A dietary intervention to increase omega-3 EPA/DHA status has also been found effective in reducing migraines and other forms of chronic headache pain.
For details and additional FAB comments and links, see:
And for more information on omega-3 for the allevation of pain, see also the following lists of articles, which are regularly updated:
20th April - MDEdge
----------------------
Key clinical point:
High-dose eicosapentaenoic acid (EPA) monotherapy for 12 weeks showed superior efficacy, safety, and tolerability in patients with episodic migraine (EM), emphasizing its potential as a promising prophylactic option for managing EM.
Major finding:
At 12 weeks, EPA vs placebo significantly improved monthly migraine frequency (P = .001), frequency of acute headache medication usage (P = .035), and headache severity (P = .030). No serious adverse events (AE) were reported, and no patients discontinued treatment due to intolerable AE.
Study details:
This 12-week randomized, double-blind, placebo-controlled clinical trial included 70 patients with EM who were randomly assigned to receive high-dose EPA (1800 mg/day; n = 70) or placebo (n = 70).
Disclosures: This study was supported by grants from Kuang Tien General Hospital, the Ministry of Science and Technology, the National Science and Technology Council (NSTC) in Taiwan, and others. The authors declared no conflicts of interest.
Source: Wang H-F, Liu W-C, Zailani H, et al. A 12-week randomized, double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain Behav Immun. 2024;18:459-467 . doi: 10.1016/j.bbi.2024.03.019 Source
Food and Behaviour Research is a registered charity (No SC034604) and a company limited by guarantee (Co No SC 253448)
Newsletter Signup
Useful Links
Contact Us
FAB Research
23 Carlton Road
Oxford
OX2 7SA
Important Notice
Medical opinion and guidance should always be sought for any symptoms that might possibly reflect a known or suspected disease, disorder or medical condition. Information provided on this website (or by FAB Research via any other means) does not in any way constitute advice on the treatment of any medical condition formally diagnosed or otherwise.
Site by Redstone Websites. Easy to Use Web Content Management. 2026 © All Rights Reserved.